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Molecular epidemiology of Klebsiella pneumoniae bacteremic strains allows for a better understanding of
preventive and therapeutic strategies. Clinical and microbiological characteristics of 348 K. pneumoniae bac-
teremia cases (2007–2009) were retrospectively characterized by multilocus sequence typing and extended-
spectrum beta-lactamases (ESBL) production. Overall, 223 (64.08%) cases were nosocomial (NA), 58 (16.67%)
healthcare associated, and 67 (19.25%) community acquired. The main infection origins were urinary tract
(16.6%, 50.0%, and 43.3%), biliary tract (10.8%, 24.2%, and 31.3%), and catheter-related infection (39.9%,
5.2%, and 0%). The 30-day mortality rate was around 20%. The rates of resistance were around 45% the highest
being among NA cases, and ESBL production was detected in 7.2% of cases. A total of 161 different sequence
types were grouped into 13 clonal sets by e-burst analysis. No relationship could be established between clonal
sets and the origin of infection or the healthcare-related settings. The high genetic variability among the isolates
suggests their intrapatient endogenous origin.
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Introduction
Klebsiella pneumoniae is an important human path-ogen in the community and in the hospital setting.
K. pneumoniae is the second most common cause of Gram-
negative bloodstream infections after Escherichia coli. This
microorganism is also well known because of the increasing
rates of antimicrobial resistance mainly associated with the
hospital setting and with extended-spectrum beta-lactamase
(ESBL) or carbapenemase production.1,2 In recent years, the
number of infections (pneumonia or urinary tract infections)
caused by drug-resistant K. pneumoniae in hospitalized patients
is increasing. Moreover, K. pneumoniae bloodstream infections
are associated with patients with comorbidities such as diabetes
mellitus, cancer, chronic liver disease, and biliary disease.3
The molecular epidemiology of multidrug-resistant (MDR)
K. pneumoniae strains and those associated with nosocomial
(NA) outbreaks has been largely studied.4,5 However, the
molecular epidemiology of K. pneumoniae causing bac-
teremia outside the hospital is less known.6 Recent studies
have defined the major lineages of K. pneumoniae, including
both NA and community-acquired isolates.7
Bloodstream infections were detected in patients with co-
morbid conditions and complications, such as diabetes mellitus
(related to community-acquired [CA] bacteremia), malignancy
(mainly related to NA bacteremia or healthcare-associated
[HCA] bacteremia) or cardiovascular diseases (mainly related
to NA).8,9
In our study, as in previous reports, urinary tract, biliary
tract, catheter, and respiratory tract were the most common
point of entry of bacteremia.3,4,10 Nowadays this is a public
health problem according to the clinical and epidemiologi-
cal impact as well as to the economic and social costs.11,12
In this study, we analyze the clinical and molecular epide-
miology of K. pneumoniae strains isolated from blood cultures
of adult patients attended over a 3-year period in a teaching
hospital, in Barcelona, Spain. Moreover, NA, HCA, and CA
bacteremia episodes caused by K. pneumoniae were analyzed.
Materials and Methods
Clinical setting
The study was carried out at the Hospital de Bellvitge, which
serves an area of *600,000 inhabitants with an average of
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30,000 admissions per year. It is a 900-bed university teaching
hospital for adult patients located in the Barcelona metro-
politan area, Spain, providing both medical and surgical
care without pediatrics, obstetrics, and burn units. As hos-
pital routine, blood cultures are performed on patients with
symptoms of infection following standardized protocols.
K. pneumoniae isolates causing bloodstream infection
from January 2007 to December 2009 were included in this
study. Clinical data of patients, including patient age, sex,
comorbidities, and infection source were prospectively
collected and included in a computerized prospective.
Definitions
NA K. pneumoniae bacteremia was considered when the
infection occurred after 48 hours of patient being admitted.
HCA K. pneumoniae bacteremia was considered when the
bloodstream infection sample was detected within 48 hours
of the patient’s admission, and it met any of the following
criteria: a patient being with health system contact (‡2 hos-
pitalization days in the 3 previous months to the recent ad-
mission, receiving any nursing care, undergoing hemodialysis
in the previous month, or nursing home residents). Finally,
CA K. pneumoniae bacteremia was considered when a pos-
itive bloodstream infection sample was detected in the first
48 hours of admission in a patient without any of the previous
criteria.13
Bacteremia was defined by the isolation of K. pneumo-
niae in blood cultures together with clinical symptoms of
infection. Two episodes were considered different when
they occurred at least 1 month apart.
Antimicrobial susceptibility testing
The minimum inhibitory concentration of antibiotics was
tested by microdilution using the commercial method Mi-
croScan (Beckman Coulter). The antibiotic susceptibility
was interpreted according to the Clinical Laboratory Stan-
dards Institute (CLSI) criteria.14 The multidrug resistance
pattern and the presence of ESBL were assessed by the
Kirby-Bauer disk diffusion method.
All multidrug-resistant strains were retested by disk dif-
fusion method following the CLSI recommendations. The
antibiotics tested were penicillins, third-generation cepha-
losporins, aztreonam, carbapenems, aminoglycosides, qui-
nolones, and cotrimoxazole. To assess the ESBL phenotype,
a double-disk diffusion test was performed to show the
synergy of cefuroxime, cefotaxime, ceftazidime, and cefe-
pime with amoxicillin/clavulanic acid.
Molecular typing
K. pneumoniae isolates were typed by pulsed-field gel
electrophoresis (PFGE) after restriction with XbaI. Band
patterns were visually compared using the criteria described
by Tenover et al.15 At least one isolate for each PFGE cluster
was subjected to Multilocus Sequence Typing (MLST) fol-
lowing protocol 2, described at the MLST web site of the
Institute Pasteur (Paris, France; http://bigsdb.web.pasteur.fr/
Klebsiella/Klebsiella.html). The allele number and Sequence
Type (ST) were assigned using this MLST website.
Bacteremia data were analyzed using the goeBURST
algorithm and an extension of the goeBURST rules to draw
a full Minimum Spanning Tree (MST). The analysis of
MLSTs was performed using Phyloviz software (https://
online.phyloviz.net/index).16
The goeBURST Full MST algorithm represents STs in a
combination of circles and lines separating the STs according
to their allelic differences.
To differentiate between the recently described
K. pneumoniae-related species (Klebsiella variicola, Kleb-
siella quasipneumoniae, and K. pneumoniae sensu stricto),
we performed a MLSA (multilocus sequence alignment) as
described previously and using the reference ST described
for these three species.17
Putative ESBL strains as deduced for the results of the
double-disk diffusion assay were subjected to a multiplex
polymerase chain reaction (PCR) assay confirming the de-
tection of blaSHV, blaTEM, blaCTX-M, and blaOXA family
genes.18 For OXA-positive strains, the PCR amplicons were
sequenced. Among CTX-M-positive strains, a PCR plus
sequencing to differentiate families CTX-M-1 and CTX-M-
9 groups was performed. Finally, because this PCR scheme
did not differentiate ESBL or non-ESBL enzymes of TEM
and SHV families, further PCR plus sequencing analy-
sis was performed19–21 (www.lahey.org/Studies). The PCR
products were sequenced by Sanger methodology at Mac-
rogen, Inc. (Seoul, Korea)
Statistical analyses
Statistical analyses were carried out using PASW Statis-
tics 18. The odds ratios (ORs) and 95% confidence intervals
were calculated, and Fisher’s exact test or chi-square test
were used for statistical analysis as appropriate. All proba-
bilities were two-tailed, and a p-value <0.05 being consid-
ered statistically significant.
Results
Microbiological and clinical features of patients
with NA, HCA, or CA bacteremia due to K. pneumoniae
During the study period ( January 2007 to December
2009) 348 episodes of Klebsiella spp. bacteremia were de-
tected in 335 patients. Eleven patients had two episodes and
one patient had three episodes (defined as those occurred at
least 1 month apart).
Table 1 shows the characteristics of the 348 bacteremia
episodes in the three groups analyzed. The overall mean age
(–standard deviation) was 63.73 – 15.81 years and 210/348
(60.35%) were males.
Fifty-three (15.2%) episodes were considered primary
bacteremia: 41 NA isolates versus 6 HCA isolates versus 6
CA isolates. There were differences in the foci of infection
comparing the three groups (NA vs. HCA vs. CA): catheter-
related bacteremia (39.9%, 5.2%, 0%) was more frequent
among NA episodes, whereas the urinary tract (16.6%, 50%,
43.3%) and biliary tract origin (12.6%, 29.3%, and 37.3%)
were more frequently found among HCA and CA infections.
The presence of underlying diseases was similar for the
three groups of patients. Diabetes mellitus, malignancy, and
cardiovascular disease were the most frequent comorbidities
among NA patients (22.9%, 39%, and 30.5%), HCA patients
(27.6%, 60.3%, and 30.5%), and CA patients (32.8%, 14.9%,
and 28.3%).






















































The median length of hospitalization was 23.6 (0–99) days
in patients with NA bacteremia. The overall 30 days mortality
was also higher among NA episodes (23.8%, 20.7%, and
16.4%, NA, HCA, and CA, respectively); however, these
differences did not reach statistical significance (Table 1).
Most of NA bacteremia episodes occurred in patients ad-
mitted to intensive care 99 (44.4%), hematology 23 (10.3%),
or surgery 18 (8.1%) wards.
Differences of antimicrobial resistance rates for K. pneu-
moniae bacteremic isolates were detected among NA, HCA,
and CA. In general, NA isolates had higher resistance rates
than those of HCA and CA: (NA vs. HCA vs. CA) for
amoxicillin/clavulanic acid (25.1%, 13.8%, and 10.5%), gen-
tamicin (5.8%, 1.8%, 0%), tobramycin (13.4%, 3.5%, 0%),
amikacin (8.5%, 1.7%, 0%), cotrimoxazole (24.7%, 17.3%,
10.4%), and ciprofloxacin (32.3%, 24.1%, 17.9%). The ESBL
Table 1. Analysis of Demographic Data and Source of Bacteremia Among Nosocomial,
Healthcare-Associated, and Community-Acquired Klebsiella pneumoniae Bacteremia Cases
Characteristics
NA N = 223
(64.1%)
HCA N = 58
(16.7%)








Mean age 61.5 (–15.815) 65.4 (–13.270) 69.8 (–16.266) 0.088 0 0.102
Sex (male) 62.8% 60.3% 52.2% 0.733 0.122 0.363
Source of bacteremia
Primary bacteremia 41 (18.4) 6 (10.3) 6 (8.9) 0.144 0.066 0.793
Urinary tract 37 (16.6) 29 (50) 29 (43.3) <0.001 <0.001 0.025
With urinary catheter 34 (15.2) 15 (25.9) 0 0.058 <0.001 <0.001
Without urinary catheter 3 (1.4) 14 (24.2) 29 (43.3) 0 0 0.025
Intra-abdominal
Abdominal 12 (5.4) 2 (3.5) 4 (6) 0.547 0.854 0.510
Biliary tract 24 (10.8) 14 (24.2) 21 (31.3) 0.008 <0.001 0.370
SBP 3 (1.3) 1 (1.7) 2 (3) 0.828 0.366 0.646
Liver abscess 1 (0.5%) 2 (3.5) 2 (3) 0.048 0.072 0.882
Soft tissues and skin 3 (1.3) 0 1 (1.5) 0.374 0.929 0.350
Pneumonia 10 (4.5) 1 (1.7) 2 (3) 0.334 0.589 0.646
Catheter-related bacteremia 89 (39.9) 3 (5.2) 0 <0.001 0 0.059
Other focus 3 (1.3) 0 0 0.374 0.340 0
Main underlying diseases
Diabetes mellitus 51 (22.9) 16 (27.6) 22 (32.8) 0.453 0.110 0.524
Malignancy 87 (39) 35 (60.3) 10 (14.9) 0.003 <0.001 <0.001
Cardiovascular disease 68 (30.5) 7 (12.1) 19 (28.3) 0.005 0.879 0.025
Chronic lung disease 27 (12.1) 8 (13.8) 11 (16.4) 0.729 0.409 0.684
Cerebrovascular disease 22 (9.9) 5 (8.6) 5 (7.5) 0.775 0.810 0.811
Chronic liver disease 13 (5.8) 6 (10.3) 9 (13.4) 0.223 0.061 0.596
End-stage chronic renal failure 4 (1.8) 5 (8.6) 0 0.008 0.577 0.014
Solid organ transplant 13 (5.8) 4 (6.9) 4 (6) 0.762 1 0.832
30-Day mortality 53 (23.8) 12 (20.7) 11 (16.4) 0.621 0.241 0.539
Significant differences are indicated in boldface.
CA, community-acquired; HCA, healthcare-associated; NA, nosocomial; SBP, spontaneous bacterial peritonitis in hepatic cirrhosis
patients.
Table 2. Rates of Antimicrobial Resistance Among Nosocomial, Healthcare-Associated,
and Community-Acquired K. pneumoniae Bacteremia
Episodesa
NA N = 223
(64.1%)
HCA N = 58
(16.7%)








Amox/clav 56 (25.1) 8 (13.8) 7 (10.5) 0.067 0.011 0.566
Piper/taz 44 (19.7) 5 (8.6) 4 (6) 0.047 0.008 0.568
Cefotaxime 24 (10.8) 4 (6.9) 2 (3) 0.381 0.051 0.308
Ceftazidime 33 (14.8) 4 (6.9) 2 (3) 0.113 0.009 0.308
Cefepime 24 (10.8) 4 (6.9) 2 (3) 0.381 0.051 0.308
Gentamicin 13 (5.8) 1 (1.7) 0 0.200 0.044 0.281
Tobramycin 30 (13.4) 2 (3.5) 0 0.033 <0.001c 0.125
Cotrimoxazole 55 (24.7) 10 (17.3) 7 (10.4) 0.232 0.011 0.269
Ciprofloxacin 72 (32.3) 14 (24.1) 12 (17.9) 0.230 0.031 0.392
Amikacin 19 (8.5) 1 (1.7) 0 0.073 0.009 0.281
Antimicrobial susceptibilityb 115 (51.6) 34 (58.6) 43 (64.2) 0.338 0.093 0.524
aAfter excluding outbreak isolates, these antimicrobial resistance rates were close similar to those of CA and HCA isolates (data not shown).
bSusceptible isolates to all antimicrobial tested, with the exception of ampicillin, piperacillin, and ticarcillin.
cSignificant differences are indicated in boldface.






















































production according to the positivity of double-disk diffusion
test was detected in 24 (10.8%) episodes of NA, in 4 (6.9%) of
HCA, and in 2 (3%) of CA. All of the ESBL producers be-
longed to Kp I-K. pneumoniae.
After sequencing, 5 of 30 isolates with positive double-
disk synergy were not classified as ESBL. These five strains
had one or two beta-lactamases: SHV-1 plus TEM-1 (n = 2),
SHV-1 plus TEM-1 plus OXA-1 (n = 1), SHV-11 plus TEM-1
(n = 1), and SHV-83 (n = 1). The remaining 25 strains showed
different beta-lactamase production patterns as shown in
Table 3. The blaCTX-M was the most common ESBL. Of note,
the presence of more than one ESBL in eight strains (Table 3).
Comparative of molecular typing in NA, HCA,
and CA bacteremia
Molecular typing of bacteremias was performed by PFGE
and MLST. Although we identified minor clusters among
NA isolates, a high genetic diversity was observed in all
three groups. In fact, the Simpson’s diversity index was
0.983 in NA, 0.988 in HCA, and 0.996 in CA.
Overall, by PFGE/MLST analysis we obtained 161 dif-
ferent STs. By groups using Phyloviz software, we found
127 STs among 191 NA isolates, 42 STs among 54 HCA
isolates, and 55 STs among 59 CA isolates. Fourteen STs
were found in NA and HCA isolates, 14 STs in NA and CA,
and 3 STs in HCA and CA. Finally, seven STs were found in
all three groups: ST13, ST15, ST17, ST35, ST37, ST42, and
ST45 (Supplementary Table S1 [Supplementary Data are
available online at www.liebertpub.com/mdr] and Fig. 1).
Seventeen STs (shared by three or more isolates) accounted
for 38.1% of the isolates.
After e-burst analysis, there were 13 clonal groups (GC1–
CG13; defined as an ST and single locus variant [SLV]), and
125 singletons. The 13 clonal sets accounted for 123 isolates;
however, there were differences among them (Supplementary
Table S1). There was 28 singletons with more than one iso-
late (n = 87 isolates) and 97 singletons, which only presented
one isolate. For instance, clonal complex 14 accounted for 28
isolates with 5 STs. Most of them had caused NA bacteremia.
In fact, this CC14 was related to an outbreak of K. pneu-
moniae producing OXA-1 beta-lactamase in our hospital.22
Other clonal groups accounting for more than 10 isolates
were associated either with CA, NA, and HCA episodes.
The same occurred among the 28 singletons accounting for
more than one isolate. When the origin of bacteremia was
analyzed, no relationship between ST and focus of infection
could be established (Supplementary Table S2).
By MLSA analysis (Fig. 2), the species distribution was
as follows: Kp III-K. variicola n = 25 (8.1%); Kp II-K.
quasipneumoniae n = 16 (5.2%), Kp I-K. pneumoniae sensu
stricto n = 266 (86.6%), being similar in all three groups by
CA, NA, and HCA.
Discussion
Klebsiella pneumoniae is an important cause of Gram-
negative bacteremia all over the world and has been largely
analyzed in the hospital setting causing infections due to
multiresistant strains.9,23–26 In addition, K. pneumoniae is a
frequent cause of other endogenous NA infections without
bacteremia (urinary tract infection, surgical infection, etc.),
although some geographical differences have been de-
tected.8,10 In the community, K. pneumoniae is the second
cause of both urinary tract infections and Gram-negative
CA bacteremia.27–29 In this study, we analyzed clinical and
molecular characteristics associated with K. pneumoniae
bacteremia, including NA, HCA, and CA episodes.13
Our study, in agreement with others, shows that
K. pneumoniae bacteremia has different clinical features in
the community or in the hospital.9 Moreover, healthcare-
related episodes were similar to CA ones. There were dif-
ferences regarding the foci of infection, the urinary and the bile
tract being the most frequent origin in the CA and HCA,
whereas catheter-related bacteremia was the most frequent
among NA cases. In our series, as in others from Europe and
North America, the bile tract is a main origin of K. pneumoniae
bacteremia in outpatients, whereas in Asian or Oceania coun-
tries the origin related to liver abscess is more frequent.3,9,29,30
In any case, K. pneumoniae bacteremia occurred mainly in
elderly patients with underlying conditions. As described for
other infections, diabetes mellitus was an important underlying
disease for K. pneumoniae bacteremia in all the three groups.6,26
Malignancy was mainly present among HCA and NA bacter-
emia episodes; in fact, this microorganism is a frequent cause of
Gram-negative bacteremia in these patients.31 Although the
highest mortality rate was found among patients with NA bac-
teremia, these differences were not statistically significant and
were similar to those found by other authors.9,32–34
In our study only 7.2% of the isolates produced an ESBL
and these were mainly associated with CTX-M family.2,35,36
Table 3. Extended-Spectrum Beta-Lactamases
Production Patterns Among Nosocomial,
Healthcare-Associated, and Community-Acquired
K. pneumoniae Bacteremia








Total number of ESBL
producers
21 (9.4) 4 (6.9) 0







CTX-M-1 and SHV-11 1 0 0
CTX-M-1 and SHV-2 1 0 0




CTX-M-9 and SHV-1 1 0 0
CTX-M-9 and SHV-11 1 0 0
CTX-M-9 and SHV-2 1 0 0
CTX-M-9 and SHV-2A 1 0 0
CTX-M-9 and SHV-12 1 0 0







SHV-2 and TEM-1 2 0 0
Non-ESBLs are underlined (SHV-1, SHV-11, TEM-1, and OXA-1).
ESBL, extended-spectrum beta-lactamases.



































































































































































































































































































































Longer hospitalization, invasive procedures, and inappropriate
antibiotic therapy or antibiotic use could raise the prevalence
of resistant strains or ESBL-producing K. pneumoniae.9,25,33 In
the early 1990s and 2000s the ESBL-producing K. pneumoniae
were associated with the hospital setting. However, the number
of HCA and CA ESBL infections is currently increasing.2,4,35,36
Nevertheless, community-acquired ESBL–K.pneumoniae in-
fections were infrequent in our series, reflecting that hospi-
tal environment is a predominant site to disseminate these
strains.3,4,32,36 In this way, the higher antibiotic resistance rates
were associated with NA cases. However, these rates were
similar to CA or HCA isolates when the clonal outbreak-
related isolates were excluded. On the other hand, the rates
of quinolone and cotrimoxazole resistance were up to 10% and
15% for CA and HCA isolates, which preclude their use
as empirical therapy in this setting. Moreover, the presence
of mobile elements with resistance determinants to fluor-
oquinolones and to cotrimoxazole has been described for other
pathogens, such as E. coli.2,37,38
The genetic diversity of K. pneumoniae isolates has
not been extensively studied outside hospital outbreaks. In
the present study, we analyzed this diversity and we found
a high heterogeneity among the isolates. However, some
clonal groups were found and were present in both the
hospital and the community. Moreover, we found some
antibiotic-susceptible strains with STs previously associ-
ated with ESBL or carbapenemase-producing strains.39–42
For instance, all ST20 isolates in our series were antibiotic
susceptible, whereas this ST has been associated with
KPC- or NDM-producing isolates. However, all four iso-
lates of this ST20 caused NA or HCA bacteremia, and this
is probably a hospital-adapted clone with the ability to
acquire resistance determinants.
Nevertheless, the high genetic variability among NA
K. pneumoniae bacteremia isolates suggests that these in-
fections had an endogenous origin. Despite the heterogene-
ity, the major cluster (CG1) included 16 patients with NA
bacteremia episodes caused by ST14 strain harboring blaOXA-1
gene and resistant to quinolones and aminoglycosides.22
We could not link the origin of infection with specific STs
or clonal complex (CC), including the hypervirulent clones.
For instance, ST23 commonly associated with patients with
pyogenic liver abscess was also found causing catheter-
related bacteremia as described previously.43 Similar results
were observed in other studies, where no relationship was
detected between pathogenicity of strains and specific
MLST.26 It seems that K. pneumoniae infections varied re-
garding clinical characteristics of patients, geographic distri-
bution of serotypes, and the presence of epidemic strains.29,44
The present study has two main limitations: first, it was
performed at a single hospital; and second, the molecular
typing was performed retrospectively, and some cases were
missing. However, it is an important series which improves
the knowledge of molecular features of K. pneumoniae
causing bacteremia and its relationship with the origin of
infection and the contact with the healthcare system.
Conclusions
This study shows a high genetic variability among
K. pneumoniae isolates causing bacteremia and suggests they
may be considered endogenous infections. The higher resistance
rates observed in the hospital setting could be linked to an NA
outbreak. Finally, high-risk clones associated to MDR could be
found as susceptible in the healthcare-related settings.
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Carratalà. 2014. Bloodstream infections in patients with solid
tumors: epidemiology, antibiotic therapy, and outcomes in
528 episodes in a single cancer center. Medicine (Baltimore)
93:143–149.






















































32. Hongsuwan, M., P. Srisamang, M. Kanoksil, N. Luanga-
sanatip, A. Jatapai, N.P. Day, S.J. Peacock, B.S. Cooper,
and D. Limmathurotsakul. 2014. Increasing incidence of
hospital-acquired and healthcare-associated bacteremia
in northeast Thailand: a multicenter surveillance study.
PLoS One 9:e109324.
33. Wolfe, C.M., B. Cohen, and E. Larson. 2014. Preval-
ence and risk factors for antibiotic-resistant community-
associated bloodstream infections. J. Infect. Public Health
7:224–232.
34. Chetcuti Zammit, S., N. Azzopardi, and J. Sant. 2014.
Mortality risk score for Klebsiella pneumoniae bacteraemia.
Eur. J. Intern. Med. 25:571–576.
35. Calbo, E., and J. Garau. 2015. The changing epidemiology
of hospital outbreaks due to ESBL-producing Klebsiella
pneumoniae: the CTX-M-15 type consolidation. Future
Microbiol. 10:1063–1075.
36. Webster, D.P., B.C. Young, R. Morton, D. Collyer, B.
Batchelor, J.F. Turton, S. Maharjan, D.M. Livermore, P.
Bejon, B.D. Cookson, and I.C.J.W. Bowler. 2011. Impact
of a clonal outbreak of extended-spectrum b-lactamase-
producing Klebsiella pneumoniae in the development and
evolution of bloodstream infections by K. pneumoniae and
Escherichia coli: an 11 year experience in Oxfordshire,
UK. J. Antimicrob. Chemother. 66:2126–2135.
37. Talan, D.A., A. Krishnadasan, F.M. Abrahamian, W.E.
Stamm, and G.J. Moran; Group for the EmergeIDNETS.
2008. Prevalence and risk factor analysis of trimethoprim-
sulfamethoxazole- and fluoroquinolone-resistant Escher-
ichia coli infection among emergency department patients
with pyelonephritis. Clin. Infect. Dis. 47:1150.
38. Rodrı́guez-Martı́nez, J.M., C. Velasco, I. Garcı́a, M.E.
Cano, L. Martı́nez-Martı́nez, and A. Pascual. 2007. Char-
acterisation of integrons containing the plasmid-mediated
quinolone resistance gene qnrA1 in Klebsiella pneumoniae.
Int. J. Antimicrob. Agents 29:705–709.
39. Ruiz-Garbajosa, P., T. Curiao, M. Tato, D. Gijón, V. Pintado,
A. Valverde, F. Baquero, M.I. Morosini, T.M. Coque, and R.
Cantón. 2013. Multiclonal dispersal of KPC genes follow-
ing the emergence of non-ST258 KPC-producing Klebsiella
pneumoniae clones in Madrid, Spain. J. Antimicrob. Che-
mother. 68:2487–2492.
40. Jin, Y., C. Shao, J. Li, H. Fan, Y. Bai, and Y. Wang. 2015.
Outbreak of multidrug resistant NDM-1-producing Klebsiella
pneumoniae from a neonatal unit in Shandong Province,
China. PLoS One 10:e0119571.
41. Bialek-Davenet, S., A. Criscuolo, F. Ailloud, V. Passet, L.
Jones, A.S. Delannoy-Vieillard, B. Garin, S. Le Hello, G.
Arlet, M.H. Nicolas-Chanoine, D. Decré, and S. Brisse. 2014.
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